Abstract. Breast cancer is the most frequent cancer in females worldwide and it has long been known that multiple genetic rearrangements correlate with complex biology and clinical behavior. In addition, copy number variations (CNVs) of DNA sequences account for a significant proportion of normal phenotypic variation and may have an important role in human pathological variation. In this study, we carried out a high-density oligonucleotide array comparative genomic hybridization (CGH) analyses in a series of breast cancer cell lines to identify novel homozygous deletion loci. The results were confirmed by quantitative PCR (Q-PCR) and 4 genes, the REV1L, ZNF14, NPAS1 and APOBEC3B genes, were selected. Analyses of 30 microdissected human breast tumors and paired normal mammary tissue samples indicated that these homozygous deletions are small-scale deletion polymorphisms. The variation in copy number at the loci of the 4 genes in blood-derived DNA demonstrated the frequency of deletions including homozygous deletions and single copy variants to be higher in breast cancer patients than healthy females. Notably, the homozygous deletion of APOBEC3B involved part of exon 5 and seemed to be cancer-specific in some patients, indicating that this is a functionally important structural variant. These copy number changes may play an important role in breast cancer and array-CGH analyses can thus be expected to provide new insight into the genetic background of breast cancer.
Introduction
Breast cancer is the most common malignancy and the most deadly cancer among women worldwide. With advances in molecular biological analyses, a number of genes involved in the development and progression of breast cancer have been isolated and shown to have abnormalities in breast cancer patients. Breast cancer is a heterogeneous disease comprising tumors differing remarkably in clinical behavior (1) and numerous genes controlled by complex regulatory networks are thought to be involved in its development and progression.
CGH has been widely used to analyze the pattern of unbalanced genomic aberrations in several types of human cancer, including breast cancer (2) (3) (4) . Recent studies have used higher resolution array-based CGH to show the enormous complexity of breast cancer cell genomes and have raised attention regarding genomic variation such as deletions, inversions and copy number variations (5) . It is thought that these variations account for a significant proportion of normal phenotypic variation and have an important role in human pathological variation (6) , but the structure and biological function of these variants remain largely unknown.
In the present study, we carried out a high-resolution arraybased CGH analysis to scan for homozygous deletions in patients with breast cancer. We found the same chromosomal alterations described previously and further identified new small-scale homozygous deletions at 2q11. 1, 19p13.3, 19q13 .2 and 22q13.1 involving the REV1L, ZNF14, NPAS1 and APOBEC3B genes, respectively. We also compared the frequency of these deletions between breast cancer patients and healthy female volunteers, and determined the homozygous regions of these genes.
Materials and methods

Cell lines and clinical specimens.
The following 25 human breast cancer cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA): AU565, BT474, DU4475, HCC38, HCC70, HCC202, HCC1143, HCC1187, HCC1419, HCC1428, HCC1569, HCC1806, HCC1954, HCC2157, MCF7, MDA-MB-157, MDA-MB-231, MDA-MB-330, MDA-MB-361, MDA-MB-435S, MDA-MB-468, SK-BR-3, UACC812, UACC893, ZR-75-1, and were maintained under the conditions recommended by the supplier.
Samples of primary breast tumors and paired normal mammary tissues were obtained from a series of 30 patients, median age 56.9 (range 33-83) years who underwent surgery in 2003-2004 at the Japanese Foundation for Cancer Table I . Forty-one homozygous deletion sites in 25 human breast cancer cell lines detected by array-CGH.
Chromosome position  Gene  Description  Deleted cell line  symbol   -----------------------------------------------------------------------------------------------------A_14_P107780 chr1:193477721-193477780 CFHL3  Homo sapiens complement factor H-related 3  HCC70, HCC2157   (CFHL3), Array CGH analysis. Array-based CGH was performed with Agilent Human Genome CGH Microarray kit 44B (Agilent Technologies, CA, USA). This array is a 60-mer oligonucleotide-based microarray that contains 42,896 biological probes sourced from the National Center for Biotechnology Information. Direct labeling reactions were per-formed with 3 μg of genomic DNA and a BioPrime Array CGH Genomic Labeling Module (Invitrogen, CA, USA) according to the manufacturer's instructions in a volume of 50 μl with 60 μM Table I . Continued.
Chromosome position Gene symbol Description Deleted cell line -
Cy5-dUTP (for the experimental sample) or Cy3-dUTP (for the reference, normal female 46, XX). The microarrays were hybridized in an Agilent microarray hybridization chamber, and hybridization was carried out for 40 h at 65˚C in a hybridization oven at 20 rpm. Following posthybridization washes, the array was scanned with an Agilent Microarray G2565AA scanner. Fluorescence intensity was extracted using Agilent Feature Extraction 8.5 software.
CGH data analysis. The data obtained from the Agilent Feature Extraction software were analyzed using Agilent CGH analytics software version 3.4. For each spot on the array, log 2 -ratios of the Cy3-labeled experiment sample vs. the Cy5-labeled reference sample were calculated. Calculated ratios were plotted against chromosomal base-pair locations obtained from the University of California-Santa Cruz (UCSC) genome browser in May 2004 and displayed chromosomal deletions or amplifications at multiple zoom levels simultaneously.
PCR.
Conventional PCR was performed with 10 ng of DNA template in a total volume of 25 μl using a Takara Ex Taq (Takara Biomedical, Japan). The reaction profile was one cycle of 94˚C for 5 min followed by 30 cycles of 94˚C for 30 sec, 60˚C for 30 sec, and 72˚C for 15 min. PCR products were assessed by ethidium bromide agarose gel electrophoresis. Primers were designed using Primer 3 to span a 100-300 bp non-repetitive region (Table I) .
Q-PCR was performed with 5 ng of DNA template in a total volume of 25 μl using a POWER SYBR-Green PCR Master Mix (Applied Biosystems, CA, USA) and an ABI Prism 7900HT (Applied Biosystems). The reaction profile was one cycle of 95˚C for 10 min followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. At the end of the reaction, samples were subjected to a melting analysis to confirm the specificity of the amplicon. We designed the primer on including the CGH target probe or as near as possible using Primer 3 to span a 100-150 bp non-repetitive region. GAPDH was used as a reference. Primer sequences for the targets in this study are listed in Table II . Quantification is based on a standard curve made from serial dilutions of normal genomic DNA within the range 0.2-125 ng. Each experiment was performed in triplicate and means are reported. Copy number changes of target genes relative to GAPDH and the calibrator were determined by using the formula: (S target /S GAPDH )/(C target /C GAPDH ) where S target and S GAPDH are the mean quantity from sample DNA using the target and GAPDH, and C target and C GAPDH are the quantity from reference DNA using the target and GAPDH. Referring to previous studies (7-9), we separated the results into 4 groups as follows: 0 copy number group (mean calculation ratio was ≤0.2), 1 copy number group (0.3-0.7), 2 copy number group (0.8-1.2), and amplification copy number group (≥1.3). Hard to classify data were placed in the borderline group.
Results
DNA copy number variation in human breast cancer cell lines. First, we performed CGH on 25 human breast cancer cell lines and constructed array-CGH profiles. When the pattern of DNA copy number changes detected by array-CGH was visualized as a function of the nucleotide position of genes, gain or loss copy number changes were observed on all of the chromosomes. Noticeably, chromosomes 1q,  5p, 6p, 7p, 8q, 10p, 10q, 11q, 16p, 17q, 19p, 19q and 20q Table II . PCR primers for 16 homozygous deletion sites. 
-----------------------------------------------------------------------------------------------------
Probe numbers are available from Agilent web resource (http://www.home.agilent.com).
contained more genes undergoing frequent copy number changes, whereas the high frequency gene deletions were observed on 8p, 9p, 17p, 18q, Xp and Xq. Several regions previously reported to have alterations in copy number in breast cancer were again identified in the current analysis, such as 1q, 5p, 7p, 8q, 11q, 17q and 20q (region of DNA copy number gains), and 9p and 17p (region of losses) (10) (11) (12) .
In the present study, we focused on sites of novel homozygous deletions in human breast cancer. We did not apply any filters to the CGH array data sets. A search was performed for genes that displayed a theoretical threshold of a 2.5-fold (log 2 ratio = -2) decrease in the tumor sample (Cy5) compared to the reference (Cy3). However, the only loci with probes on these arrays whose measured log 2 ratios were below -3 in at least 2 cell lines were selected as candidate homozygous deletion regions, because it was necessary to allow for a small margin of error and cell lines often develop artificial gene amplifications during long-term culturing. Forty-one probes (log 2 -ratio range -3.09 to -6.47) were selected as shown in Table I . Ten probes corresponded to known copy number changes of breast cancer-related genes, including CDKN2A (2 probes), CDKN2B (4 probes) (13), MTAP (1 probe) (14) , RB1 (1 probe) (15), MAP2K4 (1 probe) (16) and GSTT1 (1 probe) (17). These 10 probes were then removed from our analyses. Furthermore, 23 probes including the 10 above were contiguous with at least 2 probes in a region of known copy number change at 9p.21.1-21.3 (3 Mb, 21 probes including CDKN2A, CDKN2B and MTAP), and 17p.11.2 (5 Kb, 2 probes including MAP2K4). Finally, 25 of 41 probes were excluded to identify sites of novel smallscale homozygous deletions. The remaining 16 probes were not contiguous and did not overlap known breast cancerrelated genes (Table II) . Next, Q-PCR was performed to confirm the array-CGH data for these 16 probes as candidate sites for homozygous deletions. Ten regions did not show a homozygous deletion in any of the 25 breast cancer cell lines whereas the remaining 6 regions showed homozygous deletions consistent with the CGH array data (data not shown). We selected these 6 regions for further analysis. One copy loss variants were also observed: REV1L in 9 tumors (30%), ZNF14 in 7 tumors (23.3%), NPAS1 in 2 tumors (6.7%), and APOBEC3B in 9 tumors (30%) (Fig. 1) . However, no tumors showed a homozygous deletion of the BET1L gene (11p15.5) or chr19: 40543992-40544045 (19p13.1) and so these 2 regions were excluded (data not shown).
Homozygous deletion in primary breast
Subsequently, we performed Q-PCR with 30-paired normal mammary tissues to establish whether the 4 homozygous deletions described above were specific to tumors. Homozygous deletions of the REV1L, ZNF14, or NPAS1 gene were observed in normal mammary tissues obtained from the patients who had homozygous deletions in cancer tissues as shown in Fig. 1 . Additionally, single copy loss variants were found at REV1L in 13 patients (43.3%), ZNF14 in 9 patients (30%), and NPAS1 in 9 patients (30%). The loss of one copy in normal tissue was observed in the same patients that had a single copy loss in the tumor. The results suggested that these 3 regions are deletion polymorphisms that are frequently observed in breast cancer patients. On the other hand, homozygous deletions of APOBEC3B in paired normal samples were observed in 3 of 5 tumor homozygous deletion cases, but 2 cases (sample number: 8824, 8962) had one copy loss in paired normal samples. In addition, one copy loss variant was also found at APOBEC3B in 9 tumors (30%), and 3 of 9 cases (sample number: 8720, 8734, 8743) had two copy of APOBEC3B in paired normal samples. Thus, the homozygous deletion or one copy loss of APOBEC3B seemed to be tumor-specific in some patients. These findings indicate that the APOBEC3B gene had both a deletion polymorphism and a specific deletion copy number change for breast cancers.
Frequency of deletion polymorphisms in breast cancer patients and healthy volunteers.
To determine the incidence of homozygous deletions of the APOBEC3B, REV1L, ZNF14, and NPAS1 genes, we carried out Q-PCR with 50 pre-treatment breast cancer patients and 50 healthy female volunteers whose genomic DNA samples were prepared from peripheral blood. Homozygous deletions of the APOBEC3B gene were observed in 7 of the breast cancer patients (14%) and 2 (4%) of the volunteers (Fig. 2) . Homozygous deletions of the other three genes, the REV1L, ZNF14, and NPAS1 genes, were detected in 4 (8%), 2 (4%) and 9 (18%) of the patients and in 4 (8%), 1 (2%) and 14 (28%) of the volunteers, respectively. Deletions, especially of the APOBEC3B gene, were more frequent among the breast cancer patients than the volunteers [odds ratio (breast cancer patient/healthy group) = 3.906, P=0.0806, 95% CI, 0.77-19.83]. The deletion polymorphisms (including one copy loss variants) of these 4 genes were slightly more frequent in breast cancer patients than healthy females except for NPAS1 (Fig. 2) . In a series of 80 breast cancer samples (30 postoperative breast cancer patients and 50 preoperative breast cancer patients), no significant association between the influence of deletion polymorphisms and clinicopathological features including clinical stage, estrogen and progesterone receptor status, HER2 status, family history, and distant metastasis was found.
Detection of small-scale homozygous deletions. To determine the homozygous region of 4 genes, DNA isolated from blood samples was analyzed. The PCR analyses against genomic DNA using contiguous primers including the CGH target probe revealed that the homozygous deletions of REV1L, ZNF14, NPAS1 and APOBEC3B genes were >1.9, 7.5, 2.2 and 4 kb in size, respectively (Fig. 3) . Although the homozygous deletions of all these genes except APOBEC3B did not include an exon domain, homozygous A B deletions of APOBEC3B were observed in part of exon 5. RT-PCR targeting exon 5 demonstrated that RNA of APOBEC3B was expressed in controls (healthy volunteers, wild-type), but was not detected in breast cancer patients that showed homozygous deletions (data not shown).
Discussion
CNVs account for a significant proportion of normal phenotypic variation and may have an important role in human pathological variation (6) . CNVs can be simple in structure, such as tandem duplications, or may involve complex gains or losses of homologous sequences at multiple sites in the genome (18) . According to recent studies using BAC-array and SNP-array technology, CNVs ranging in size from kilo bases to mega bases are more common in the human genome than previously thought (5, 19) , and several databases of deletions and amplifications are already available (20, 21) . On the other hand, it has long been known also that chromosomal deletions can lead to genomic disorders (22) , though it was thought that chromosomal deletions causing severe disease were rare in populations. However, recent study has indicated that more benign deletions are widespread in the human genome (20) , and several polymorphic deletions are related to carcinogenesis (23) .
In the present study, 4 novel small-scale homozygous deletion loci were identified in breast cancer. We performed a genome-wide analysis of changes in DNA copy number, especially sites of homozygous deletions, in breast cancer, by way of oligo array-based CGH, on 44B microarrays. Scanning for homozygous deletions was undertaken in 25 breast cancer cell lines. The agilent 44B array interrogates over 
A B
array data sets to identify candidate deletion loci, because the detection of microdeletions enables the identification of novel tumor suppressor genes, and biomarkers associated with cancer. Several genes previously shown to have homozygous deletions were also identified in the current study, including the CDKN2A, CDKN2B, MTAP, RB1, MAP2K4 and GSTT1 genes whose loci were detected as regions containing at least 2 consecutive probes. However, 4 homozygous deletion loci containing the REV1L, ZNF14, NPAS1 and APOBEC3B genes were recognized by one probe that was not contiguous. We have further demonstrated that the range of homozygous deletions of these 4 genes was >8 kb. This led us to consider the possibility that high-resolution CGH array technology allows the detection of novel smallscale deletion loci of breast cancer-related genes.
The analysis of breast cancer patients showed that homozygous deletions of REV1L, ZNF14, and NPAS1 were observed not only in microdissected tumor tissues but also in matched normal tissues. It was suggested that these homozygous deletions are polymorphisms. However, homozygous deletions of APOBEC3B showed tumor specificity in some cases. These findings suggested that the locus of the APOBEC3B gene had both deletion polymorphisms (copy number polymorphisms) and tumor-specific deletion copy number changes for breast cancer.
APOBEC3B is a member of the cytidine deaminase family. It is thought that APOBEC3B proteins may be RNA-editing enzymes and have roles in growth or cell cycle control (24, 25) . A large deletion polymorphism including the APOBEC3 gene cluster was recently identified. Kidd et al demonstrated a large deletion of 29.5 kb that removes the APOBEC3A and APOBEC3B genes (26) . However, our results demonstrated that the homozygous deletion was >4 kb long, occurring within the APOBEC3B gene. Although this small-scale deletion was included in their large-scale polymorphism, our findings suggest that it is a novel smallscale deletion in the APOBEC3B gene.
It is worth noting that the homozygous deletion of APOBEC3B involved part of exon 5 and seemed to be tumor-specific in some patients. Furthermore, no transcription of APOBEC3B in breast cancer cells with a homozygous deletion at the APOBEC3B locus was detected (data not shown). The results suggest that this is a functionally important structural variant. There have been several reports that APOBEC3B played a role in innate cellular immunity inhibiting retroviral infections (such as HIV-1 and Mouse mammary tumor virus), the propagation of hepatitis B virus, and the retrotransposition of endogenous elements (27) (28) (29) (30) . Certainly, the role of APOBEC3B in breast cancer warrants further study.
The copy number variations at the loci of these 4 genes detected in blood-derived DNA by QPCR demonstrated that the frequency of deletions including homozygous deletions and single copy loss variants was slightly higher in breast cancer patients than healthy females except for NPAS1. Although the association between deletions of these genes and breast cancer risk needs further analysis, the identification and investigation of such small-scale deletions using the present approach may help to elucidate their effect on disease susceptibility.
In conclusion, we subjected breast cancer samples to an array-CGH analysis and found 4 regions of small-scale deletion polymorphisms. Array-CGH can thus be expected to provide new insight into the genetic background of breast cancer.
